Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies
about
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsLiposomal Formulations in Clinical Use: An Updated Review.Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicitiesPopulation pharmacokinetics of amphotericin B lipid complex in neonates.Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory activity.Tissue penetration of antifungal agents.Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.A sensitive amphotericin B immunoassay for pharmacokinetic and distribution studies.Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.Formulation and evaluation of microemulsion based delivery system for amphotericin B.Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate.
P2860
Q27025299-B973F086-78A9-45A1-A025-B0D272FB2DEBQ33850427-84EF7686-A35F-4BFF-BCCE-BEAEE373116BQ33978197-D1318CA7-0F38-45E2-9A5F-6C9E4A8D1D88Q33980885-A0CA5C9D-2846-4812-BCF5-AC550FC83151Q33981905-25C008E8-1A9D-4024-A7EB-7AACC6D070F5Q34228332-62D8A2EE-160B-4D5B-8F41-F1B451EEE34AQ37005474-B20D8DF1-6CFF-4856-9046-7631FAD382C0Q37544911-D9A25559-7106-4FCE-8599-ACDBA03C38AFQ38653256-24AAE821-DC6F-4942-A6DA-065A2302EA91Q38681635-EC5440C4-2B8D-435B-B854-E56D74FC6EF0Q39473015-04241CA7-F37E-4DB4-A1DE-9E8A7724A929Q40667866-418D2F10-67BA-482F-945B-3E825A48065CQ41833877-62252796-C7B2-4314-BA79-172294928D8AQ41897364-2ED5EF39-5626-495D-9CBB-0C60A9E79A03
P2860
Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Pharmacokinetic profile of ABE ...... m phase I and phase II studies
@en
Pharmacokinetic profile of ABELCET
@nl
type
label
Pharmacokinetic profile of ABE ...... m phase I and phase II studies
@en
Pharmacokinetic profile of ABELCET
@nl
prefLabel
Pharmacokinetic profile of ABE ...... m phase I and phase II studies
@en
Pharmacokinetic profile of ABELCET
@nl
P2093
P2860
P356
P1476
Pharmacokinetic profile of ABE ...... m phase I and phase II studies
@en
P2093
A Adedoyin
A Llanos-Cuentas
C E Swenson
D DeValeriola
E Anaissie
G Lopez-Berestein
J F Bernardo
P2860
P304
P356
10.1128/AAC.41.10.2201
P407
P577
1997-10-01T00:00:00Z